Roche Pharmaceuticals

Präsentation von elf Abstracts zu Roches Anämie-Therapien auf führendem, europäischen Nephrologiekongress

    Basel, Schweiz (ots/PRNewswire) -

    - Ergebnisse der Phase III der C.E.R.A. Studie erstmals vorgestellt

    Nephrologen, die vom 15. bis zum 18. Juli in Glasgow am 43. ERA-EDTA-Kongress (European Renal Association-European Dialysis and Transplant Association) teilnehmen, werden Gelegenheit haben, eine Reihe von Ergebnissen aus den klinischen Entwicklungsprogrammen von Roche zur Anämie-Medikationen zu erfahren.

    Zu den Höhepunkten zählt die Vorstellung erster Phase-III-Ergebnisse des klinischen Entwicklungsprogramms C.E.R.A. (Continuous Erythropoietin Receptor Activator), dem grössten seiner Art, mit Ergebnissen aus Erhaltungsstudien bei Dialysepatienten.

    Darüber hinaus werden sieben Abstracts die Untersuchungsergebnisse zu Roches existierendem Anti-Anämie-Wirkstoff NeoRecormon(R) vorstellen.

@@start.t1@@      Autor                 Titel                                Art der        Datum, Uhrzeit
                                                                    Präsentation         und Ort
      C.E.R.A.
      Presentations
      Lead Author /    Intravenous (IV)            mündlich    Sonntag, den 16. Juli
      Vortragender:    C.E.R.A. (continuous                                  2006
                                erythropoietin
      N. Levin            receptor activator)                          Sitzung: 13:45 -
                                administered once                                        15:15
                                every two weeks or
                                once monthly                                              Halle 1
                                maintains haemoglobin
                                (Hb) levels in                                    Poster ID: SO23
                                patients with chronic
                                kidney disease (CKD)
                                on Dialysis.
      Autor:                Subcutaneous (SC)          Poster        Sonntag, den 16. Juli
      W. Sulowicz        C.E.R.A. (continuous                                  2006
                                erythropoietin
                                receptor activator)                          Sitzung: 08:00 -
                                administered once                                        16:00
                                every two weeks or
                                once monthly                                        Autor anwesend:
                                maintains haemoglobin                          10:30 - 12:00
                                (Hb) levels in
                                patients with chronic                    Poster Area, Halle 4
                                kidney disease (CKD)
                                on Dialysis.                                      Poster ID: SP424
      Autor:                Intravenous (IV)            Poster        Sonntag, den 16. Juli
      B. Canaud          C.E.R.A. (continuous                                  2006
                                erythropoietin
                                receptor activator)                          Sitzung: 08:00 -
                                administered once                                        16:00
                                every two weeks
                                maintains stable                                 Autor anwesend:
                                haemoglobin (Hb)                                  10:30 - 12:00
                                levels in patients
                                with chronic kidney                        Poster Area, Halle 4
                                disease (CKD) on
                                dialysis.                                          Poster ID: SP425
      Autor                 Titel                                Art der        Datum, Uhrzeit
                                                                    Präsentation         und Ort
      Hauptautor /      Different receptor          mündlich  Sonntag, den 16. Juli
      Vortragender:    binding activity of                                    2006
                                C.E.R.A. (continuous
      M. Brandt / M.  erythropoietin                                  Sitzung: 13:45 -
      Jarsch                receptor activator)                                    15:15
                                compared with epoetin
                                beta determined by                                    Halle 1
                                surface plasmon
                                resonance and                                      Poster ID: SO18
                                competition assay on
                                UT-7 cells.
      NeoRecormon
      Präsentationen
      Autor: N. Clyne Haemoglobin control         Poster      Sonntag, den 16. Juli
                                with epoetin beta:                                      2006
                                Results from the
                                cardiovascular risk                          Sitzung: 08:00 -
                                reduction by early                                      16:00
                                anaemia treatment
                                with epoetin beta                                Autor anwesend:
                                (CREATE) and anaemia                            10:30 - 12:00
                                correction in
                                diabetes (ACORD)                            Poster Area, Halle 4
                                studies.
                                                                                         Poster ID: SP457
      Hauptautor /      Anemia correction            mündlich  Sonntag, den 16. Juli
      Vortragender:    with epoetin beta in                                  2006
                                patients with
      E. Ritz              diabetes and chronic                         Sitzung: 13:45 -
                                kidney disease -                                         15:15
                                primary results of
                                the anaemia                                                Halle 1
                                corrrection in
                                diabetes (ACORD)                                 Poster ID: SO22
                                study.
      Autor: T. Rath  Haemoglobin stability      Poster
                                with epoetin beta:
                                Results from an                                Sonntag, den 16. Juli
                                interim analysis of                                    2006
                                the gain
                                effectiveness in                                Sitzung: 08:00 -
                                anaemia treatment                                        16:00
                                with NeoRecormon
                                (GAIN) observational                          Autor anwesend:
                                study.                                                  10:30 - 12:00
                                                                                         Poster Area, Halle 4
                                                                                         Poster ID: SP453
      Autor: B.          Haemoglobin levels          Poster
      Rutkowski          and iron status in
                                haemodialysis                                  Sonntag, den 16. Juli
                                patients across                                          2006
                                Europe: Results from
                                an interim analysis                          Sitzung: 08:00 -
                                of the GAIN                                                 16:00
                                effectiveness in
                                anaemia treatment                                Autor anwesend:
                                with NeoRecormon(R)                              10:30 - 12:00
                                (GAIN) observational
                                study.                                            Poster Area, Halle 4
                                                                                         Poster ID: SP455
      Autor: F.          Treatment of renal          Poster
      Locatelli          anaemia remains
                                suboptimal despite                          Sonntag, den 16. Juli
                                revised European Best                                 2006
                                Practice Guidelines
                                (EBPG).                                              Sitzung: 08:00 -
                                                                                                 16:00
                                                                                          Autor anwesend:
                                                                                            10:30 - 12:00
                                                                                      Poster Area, Halle 4
                                                                                          Poster ID: SP448
      Autor:                Treatment of renal          Poster      Sonntag, den 16. Juli
      A. Wiecek          anaemia: Comparison                                    2006
                                between Eastern and
                                Western Europe with                          Sitzung: 08:00 -
                                respect to the                                            16:00
                                European Best
                                Practice Guidelines                            Autor anwesend:
                                (EBPG).                                                 10:30 - 12:00
                                                                                        Poster Area, Halle 4
                                                                                         Poster ID: SP447
      Autor: J.C.        Equivalence ratio in      Poster        Sonntag, den 16. Juli
      Stolear              patients switching                                      2006
                                from rhEPO to
                                darbepoetin alfa.                              Sitzung: 08:00 -
                                                                                                  16:00
                                                                                         Autor anwesend:
                                                                                          10:30 - 12:00
                                                                                    Poster Area, Halle 4
                                                                                        Poster ID: SP421@@end@@

    Interessierte Journalisten werden in Kürze den vollständigen Text der für die Präsentation ausgewählten ERA-EDTA Abstracts sowie die Tagesordnung der Veranstaltung online unter http://www.era-edta.org einsehen können.

ots Originaltext: Roche Pharmaceuticals
Im Internet recherchierbar: http://www.presseportal.ch

Pressekontakt:
Für weitergehende Informationen wenden Sie sich bitte an: Sheila Gies
bei Roche, Tel.: +1-973-235-4347, Mobiltelefon: +1-973-687-0188,
Rosemary Hennings bei Galliard Healthcare, Tel.: +44-(0)-207-663,
Mobiltelefon: +44-(0)-7799-411325



Weitere Meldungen: Roche Pharmaceuticals

Das könnte Sie auch interessieren: